williamtay
2021-12-09
Comment
DiSa partners NUS, SingHealth to commercialise new saliva-based Covid-19 ART kits
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":602666673,"tweetId":"602666673","gmtCreate":1639015830587,"gmtModify":1639015830770,"author":{"id":3574251612695532,"authorId":3574251612695532,"authorIdStr":"3574251612695532","name":"williamtay","avatar":"https://static.tigerbbs.com/c00441308daf5913d12a1f1b4ac1db1c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Comment</p></body></html>","htmlText":"<html><head></head><body><p>Comment</p></body></html>","text":"Comment","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/602666673","repostId":1157686990,"repostType":4,"repost":{"id":"1157686990","pubTimestamp":1639015308,"share":"https://www.laohu8.com/m/news/1157686990?lang=&edition=full","pubTime":"2021-12-09 10:01","market":"sg","language":"en","title":"DiSa partners NUS, SingHealth to commercialise new saliva-based Covid-19 ART kits","url":"https://stock-news.laohu8.com/highlight/detail?id=1157686990","media":"Businesstimes","summary":"DIGITAL security firm DiSa, through its subsidiary company Digital Life Line, has signed a tripartit","content":"<div>\n<p>DIGITAL security firm DiSa, through its subsidiary company Digital Life Line, has signed a tripartite licensing agreement with the National University of Singapore (NUS) and Singapore Health Services ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/disa-partners-nus-singhealth-to-commercialise-new-saliva-based-covid-19-art-kits\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiSa partners NUS, SingHealth to commercialise new saliva-based Covid-19 ART kits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiSa partners NUS, SingHealth to commercialise new saliva-based Covid-19 ART kits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 10:01 GMT+8 <a href=https://www.businesstimes.com.sg/companies-markets/disa-partners-nus-singhealth-to-commercialise-new-saliva-based-covid-19-art-kits><strong>Businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DIGITAL security firm DiSa, through its subsidiary company Digital Life Line, has signed a tripartite licensing agreement with the National University of Singapore (NUS) and Singapore Health Services ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/disa-partners-nus-singhealth-to-commercialise-new-saliva-based-covid-19-art-kits\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"532.SI":"鈞富集团有限公司"},"source_url":"https://www.businesstimes.com.sg/companies-markets/disa-partners-nus-singhealth-to-commercialise-new-saliva-based-covid-19-art-kits","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157686990","content_text":"DIGITAL security firm DiSa, through its subsidiary company Digital Life Line, has signed a tripartite licensing agreement with the National University of Singapore (NUS) and Singapore Health Services (SingHealth) for the use of new saliva-based Covid-19 antigen rapid test (ART) kits.\nDigital Life Line plans to commercialise the ART kits, subject to its ability to obtain approval from the relevant regulatory authority. The subsidiary specialises in manufacturing and distributing the new saliva-based ART kits.\nThe kits will be bundled to a system capable of reading the results from the ART cassette, before authenticating and automating the delivery of the tamper-free test results to intended recipients. The system will also include an automatic self-test kiosk and a mobile application.\nAccording to DiSa managing director and group chief executive officer Eddie Chng, the company's serialisation technology will be used to tag each unique user to an ART kit, to prevent tampering of the test result.\nDiSa highlighted the need for the ART kits to be tamper-free, considering the strong demand for these as Vaccinated Travel Lanes open up, and mandatory testing for workers from different sectors. Demand is expected to increase further as countries reopen and testing becomes more regular.\n\"Our system removes the administrative burden of the business owners who are required to do mandatory regular ART tests for their workers,\" said Chng.\nThe saliva-based ART kits were developed by NUS and SingHealth Duke NUS Academic Medical Centre. On Wednesday (Dec 8), Duke-NUS Medical School announced that the new technology could test for Covid-19 \"at the point-of-care with sensitivity higher than current ART tests and close to that of laboratory-based Polymerase Chain Reaction (PCR) tests\".\nShares of DiSa closed at S$0.002 on Dec 8, up S$0.001 or 100 per cent, before the announcement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":145,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/602666673"}
精彩评论